Combining MK626, a Novel DPP-4 Inhibitor, and Low-Dose Monoclonal CD3 Antibody for Stable Remission of New-Onset Diabetes in Mice

Combining immune intervention with therapies that directly influence the functional state of the β-cells is an interesting strategy in type 1 diabetes cure. Dipeptidyl peptidase-4 (DPP-4) inhibitors elevate circulating levels of active incretins, which have been reported to enhance insulin secretion...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Lei, Gysemans, Conny A., Stangé, Geert, Heremans, Yves, Yuchi, Yixing, Takiishi, Tatiana, Korf, Hannelie, Chintinne, Marie, Carr, Richard D., Heimberg, Harry, Pipeleers, Daniel, Mathieu, Chantal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4182446/
https://www.ncbi.nlm.nih.gov/pubmed/25268801
http://dx.doi.org/10.1371/journal.pone.0107935

Ejemplares similares

Ejemplares similares